Skip to content

Observation of clinical curative effect of Herba Desmodii Styracifolii Flavonoids Capsule in the treatment of renal calculus after ureteroscope

Observation of clinical curative effect of Herba Desmodii Styracifolii Flavonoids Capsule in the treatment of renal calculus after ureteroscope

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089687
Enrollment
Unknown
Registered
2024-09-12
Start date
2024-11-01
Completion date
Unknown
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney stone

Interventions

Intervention group:After ureteroscopy for kidney stones, the total flavone capsule was given orally, 3 capsules at a time, three times a day, and the medication cycle was 4 weeks.

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-70 years; 2. Patients with kidney stones who were not completely drained after ureteroscopy (maximum diameter of residual stones <= 6mm); 3. Patients with good renal function and moderate or lower degree of hydronephrosis on the affected side (renal pelvis separation <=15mm); 4. Postoperative ureteral stent needs to be indwelled for 2 or 4 weeks; 5. Can complete the research according to the requirements of the test plan.

Exclusion criteria

Exclusion criteria: 1. Women who are pregnant or preparing for pregnancy or breastfeeding; 2. Accompanied by serious cardiovascular, liver and gallstone (gallstone), kidney or other organs of serious organic diseases; 3. Renal ureteral junction or calculi distal ureter with deformity, stenosis, obstruction and postoperative scar adhesion; 4. Obstructive anuria, renal failure, chronic uremia, medullary sponge kidney; 5. Patients with severe urinary tract infection, patients with severe digestive system diseases (such as acute peptic ulcer, chronic ulcerative colitis, localized enteritis, intestinal obstruction); 6. Allergic or allergic to known ingredients of the drug; 7. Stone-removing drugs were used 2 weeks before surgery; 8. Severe spleen and stomach deficiency cold.

Design outcomes

Primary

MeasureTime frame
Stone free rate on the 14th day after surgery;

Secondary

MeasureTime frame
Reduction rate of analgesic use at 14 and 28 days after surgery;VAS scores improved at 14 and 28 days after surgery;Retention rate of ureteral stents at 14 and 28 days after surgery;Stone free rate on the 28th day after surgery;

Countries

China

Contacts

Public ContactKunjie Wang

Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University

wangkj@scu.edu.cn+86 189 8060 1848

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026